Welcome to our dedicated page for Nervgen Pharma news (Ticker: NGENF), a resource for investors and traders seeking the latest updates and insights on Nervgen Pharma stock.
NervGen Pharma Corp. (NGENF) generates news primarily as a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. Newsflow around NervGen often centers on clinical data from its Phase 1b/2a CONNECT SCI Study of its lead candidate NVG-291, regulatory interactions, financing activities, and capital markets developments.
Investors following NGENF news can expect detailed updates on NVG-291’s clinical progress, including topline and expanded data from the chronic cohort of the CONNECT SCI Study and ongoing enrollment in the subacute cohort. Company announcements have highlighted durable improvements in function, independence, and quality of life in individuals with chronic SCI, supported by neurophysiological measures such as changes in corticospinal and reticulospinal signaling. These releases provide insight into how NervGen interprets the efficacy profile and potential impact of NVG-291.
NervGen’s news also covers regulatory milestones, such as FDA Type C meetings and planned End-of-Phase 2 discussions, as well as designations like Fast Track from the FDA and Orphan Drug status from the EMA for spinal cord injury. Capital markets and corporate updates, including non-brokered private placements, at-the-market equity program activity, and the company’s approval for listing on Nasdaq under the symbol NGEN, are additional recurring themes.
Preclinical research updates, particularly Department of Defense–sponsored studies of NVG-291-R in models of traumatic hearing loss and peripheral nerve injury, further contribute to the news stream by illustrating the broader therapeutic potential of NervGen’s technology. For readers tracking NGENF, this news page offers a centralized view of clinical, regulatory, financing, and strategic developments as the company advances its neuroreparative pipeline.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company focused on neurorestorative therapeutics, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's President & CEO, Mike Kelly, will engage in a fireside chat on February 11, 2025, at 8:40 a.m. EST.
The conference, scheduled for February 11-12, 2025, will be held in a virtual format. NervGen's management team will be available for one-on-one virtual meetings with investors throughout the conference. A webcast of the presentation will be made available and archived for later viewing.
NervGen Pharma has completed enrollment of 20 subjects in the chronic cohort of its Phase 1b/2a clinical trial for NVG-291, its lead candidate for spinal cord injury (SCI) treatment. The company expects to release topline data in Q2 2025 after completing data collection, review, database lock, unblinding, and analysis.
The company has also received IRB approval for a protocol amendment and begun screening subjects for the subacute cohort. The trial (NCT05965700) is designed as a proof-of-concept, double-blind, randomized placebo-controlled study.
Management believes their experience from recruiting the chronic cohort, combined with the recently approved protocol amendment, will improve the recruitment process for the subacute cohort while reducing the burden on participants.
NervGen Pharma (TSXV: NGEN) (OTCQB: NGENF) has established an at-the-market equity program (ATM Program) allowing the company to issue and sell common shares through Stifel Nicolaus Canada Inc. The program has a limit of up to C$30 million in common shares, with sales occurring at prevailing market prices on the TSX Venture Exchange or other recognized marketplaces in Canada.
The ATM Program will run until December 19, 2026, unless terminated earlier. The company plans to use the net proceeds for general corporate purposes, including ongoing operations, working capital, research and development, intellectual property development, preclinical and clinical expenses, and potential future acquisitions. The program provides NervGen with enhanced flexibility for future additional financing needs.
NervGen Pharma reported Q3 2024 financial results, highlighting the approaching completion of target enrollment in the chronic cohort of their Phase 1b/2a clinical trial for NVG-291 in spinal cord injury. The company initiated preclinical studies for NVG-300 in ischemic stroke, ALS, and SCI. Financial results show cash position of $21.0 million as of September 30, 2024, with Q3 R&D expenses of $4.4 million and G&A expenses of $2.8 million. Net loss for Q3 was $5.2 million ($0.07 per share).
NervGen Pharma (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company focusing on neurorestorative therapeutics, has announced its participation in the Stifel 2024 Healthcare Conference. CEO Mike Kelly will lead a fireside chat on November 18, 2024, at 10:20 a.m. EST. The conference will be held at the Lotte New York Palace Hotel from November 18-19, 2024. Management will be available for one-on-one investor meetings during the event, and a webcast of the presentation will be available for replay.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) has announced that target enrollment for the chronic cohort in its Phase 1b/2a clinical trial of NVG-291 for spinal cord injury (SCI) is nearing completion. The study (NCT05965700) is a proof-of-concept, double-blind, randomized placebo-controlled trial. Mike Kelly, NervGen's President & CEO, expressed excitement about the progress but noted challenges in forecasting enrollment due to various factors and the study's novel design.
The company remains confident in advancing NVG-291 and will provide updates when enrollment is completed and when topline data is expected. NervGen plans to allow all subjects who have started the screening process when the 20-subject target is reached to enroll if they meet the criteria, potentially resulting in more than 20 subjects in the chronic cohort.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company, announced that its Chief Medical Officer, Daniel Mikol, MD, Ph.D., will present at the Unite 2 Fight Paralysis (U2FP) 19th Annual Science & Advocacy Symposium on September 27-28, 2024, in Atlanta, Georgia.
Dr. Mikol's presentation, titled 'Clinical Trials in Spinal Cord Injury ... Lost in Translation?', will be delivered during Session 6 on Saturday, September 28, from 11:00 a.m. to 11:20 a.m. EDT at the Atlanta Marriott Marquis. He will discuss the challenges of translating results from animal models to human clinical trials for spinal cord injury (SCI).
The U2FP Symposium is a significant event that gathers research scientists, clinicians, investors, SCI survivors, and family members to promote knowledge, collaboration, and empowerment for stakeholders dedicated to finding a cure for SCI.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company, announced that its Chief Medical Officer, Dr. Daniel Mikol, will present at the 63rd International Spinal Cord Society (ISCoS) Annual Scientific Meeting in Antwerp, Belgium, on September 23, 2024. Dr. Mikol will provide a clinical trial update on the Phase 1b/2a study of NVG-291 in individuals with subacute or chronic spinal cord injury (SCI).
The presentation will cover the trial design, rationale for evaluating clinical and electrophysiological measures, and baseline characteristics of randomized subjects. NVG-291 has shown promise in preclinical studies for promoting functional recovery through neural repair mechanisms. The company hopes that the trial results will demonstrate the potential of NVG-291 to enable neural repair in SCI patients and support further investigation.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company focused on developing treatments for nervous system damage, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel in New York City.
Mr. Mike Kelly, President & CEO of NervGen, will deliver a presentation on Tuesday, September 10, 2024, at 9:30 a.m. EDT. The company's management team will also be available for one-on-one meetings with investors throughout the conference, providing an opportunity for in-depth discussions about NervGen's innovative approaches to treating nervous system damage.
NervGen Pharma reported Q2 2024 financial results and operational updates for its Phase 1b/2a clinical trial of NVG-291 for spinal cord injury (SCI). Key highlights include:
1. Targeting completion of enrollment in the chronic cohort by Q3 2024
2. Protocol amendment submitted to enhance enrollment in the subacute cohort
3. Introduction of NVG-300 for preclinical studies in ischemic stroke, ALS, and SCI
4. Cash position of $26.6 million as of June 30, 2024
5. Q2 2024 net loss of $7.8 million ($0.11 per share)
The company is implementing strategies to increase trial awareness and participant support, while also expanding its pipeline with NVG-300, potentially providing future partnering opportunities.